Advanced Solid Tumor Clinical Trials

560 recruitingLast updated: June 17, 2026

There are 560 actively recruiting advanced solid tumor clinical trials across 44 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3, Phase 4. Top locations include Houston, Texas, United States, Shanghai, Shanghai Municipality, China, San Antonio, Texas, United States. Updated daily from ClinicalTrials.gov.


Advanced Solid Tumor Trials at a Glance

560 actively recruiting trials for advanced solid tumor are listed on ClinicalTrialsFinder across 6 cities in 44 countries. The largest study group is Phase 1 with 496 trials, with the heaviest enrollment activity in Houston, Shanghai, and San Antonio. Lead sponsors running advanced solid tumor studies include BeOne Medicines, Jiangsu HengRui Medicine Co., Ltd., and MediLink Therapeutics (Suzhou) Co., Ltd..

Browse advanced solid tumor trials by phase

Treatments under study

About Advanced Solid Tumor Clinical Trials

Looking for clinical trials for Advanced Solid Tumor? There are currently 275 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Solid Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Solid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 560 trials

Recruiting
Phase 1

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 1

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Advanced Solid TumorsMetastatic Solid Tumors
Merck Sharp & Dohme LLC178 enrolled25 locationsNCT05853367
Recruiting
Phase 1Phase 2

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

Advanced Solid Tumor
BioNTech SE375 enrolled17 locationsNCT07147348
Recruiting
Phase 1

FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

Advanced Solid TumorMetastatic Solid TumorSolid Tumor+2 more
Memorial Sloan Kettering Cancer Center16 enrolled7 locationsNCT07638371
Recruiting
Phase 1

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled17 locationsNCT05768932
Recruiting
Phase 1Phase 2

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Advanced Solid Tumor
Eikon Therapeutics156 enrolled57 locationsNCT06253130
Recruiting
Phase 1Phase 2

Study of CM518D1 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Keymed Biosciences Co.Ltd434 enrolled1 locationNCT07019779
Recruiting
Phase 1

A Study of MG2512 Injection in Participants With Advanced Solid Tumors

Advanced Solid Tumor
Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.116 enrolled2 locationsNCT07348653
Recruiting
Phase 1

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer
Deborah Doroshow23 enrolled1 locationNCT04997993
Recruiting
Phase 1

A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.

Advanced Solid Tumors
Joint Biosciences Ltd.18 enrolled1 locationNCT07648472
Recruiting
Phase 1

EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors

Advanced Solid Tumor (Phase 1)
Epics Therapeutics48 enrolled11 locationsNCT07163325
Recruiting
Phase 1

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

Advanced Solid Tumor
Daiichi Sankyo108 enrolled8 locationsNCT05765851
Recruiting
Phase 1

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.138 enrolled9 locationsNCT07360314
Recruiting
Phase 1Phase 2

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

Advanced Solid Tumors That Are MTAP Deficient
AstraZeneca334 enrolled21 locationsNCT06130553
Recruiting
Phase 1

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Advanced Solid TumorMetastatic Solid TumorEsophageal Squamous Cell Carcinoma+7 more
Plexium, Inc.155 enrolled10 locationsNCT07284186
Recruiting
Phase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen464 enrolled16 locationsNCT07403721
Recruiting
Phase 1

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Advanced Solid TumorMetastatic Solid Tumor
Coherus Oncology, Inc.154 enrolled30 locationsNCT06657144
Recruiting
Phase 1Phase 2

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

Metastatic Solid TumorLocally Advanced Solid TumorEGFR Overexpression
Yuhan Corporation80 enrolled4 locationsNCT06975410
Recruiting
Phase 1

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

Advanced Solid TumorCutaneous MelanomaUveal Melanoma, Metastatic
MonTa Biosciences ApS106 enrolled5 locationsNCT04855435
Recruiting
Phase 1

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

Advanced Solid Tumors
AstraZeneca40 enrolled11 locationsNCT07161414